Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

FOUND: Why is arcellx stock surging today | Mind Blowing Facts

Tumor,Microenvironment,Concept,With,Cancer,Cells,,T-cells,,Nanoparticles,,Cancer,Associated

Arcellx Inc. (NASDAQ:ACLX) shared new data on Saturday from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel) for relapsed or refractory multiple myeloma (RRMM).

The data was presented at the 2025 American Society of Hematology (ASH) Annual Meeting and Exposition.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.